Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Dave’s Hot Chicken® Launches Dave’s “NOT” Chicken® Cauliflower Sliders and Bites
-
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
-
OrthoPediatrics Corp. Announces Acquisition of Boston Orthotics & Prosthetics
-
Sameer Agrawal Named Chief Executive Officer of ORBCOMM
-
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
-
Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan
-
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
-
Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of "Off-the-Shelf" Stem Cell Therapies for Pets
-
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
-
Alignment Healthcare Delivers 44% Year-Over-Year Membership Growth Following Significant Boost from AEP, Increasing Membership to 155,500
-
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
-
OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Samba TV and HyphaMetrics Announce Exclusive Integration of Viewership Data and Cross-media Panel to Form the Most Unified Dataset in the Market
-
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
-
Bionano Reports Preliminary Fourth Quarter and Full-Year 2023 Results
-
Fred Di Tosto Appointed President of Martinrea International Inc.
-
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
-
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
-
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
-
Gentex Announces Partnership With Solace to Develop Next-Generation Wireless Power
-
Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation
-
Traction Uranium Announces Mobilization of Gravity Crew to Hearty Bay Project
-
BairesDev Awarded by Clutch for Consistent Excellence in Service and Client Satisfaction
-
Mesa Laboratories Appoints Mark Capone to its Board of Directors
-
STACK Infrastructure Expands its AI-Ready Data Center Capabilities to Support Machine Learning and Related High-Density Workloads
-
Shockwave Medical Provides Quarterly Earnings Release Dates for 2024
-
Singing Machine and Stingray Unveil New Karaoke Gaming & Scoring Capabilities Targeting the Automotive Market
-
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
-
Fred Di Tosto Appointed President of Martinrea International Inc.
-
SLR Investment Corp. Schedules the Release of its Financial Results for the Quarter and Fiscal Year Ended December 31, 2023
-
Stryker announces 2023 sales surpassed $20 billion
-
Compass Diversified Announces Investment Team Promotions
-
Kandou’s CFO, Jeff Winzeler, to Present at the 26th Annual Needham Growth Conference
-
STMicroelectronics Announces Status of Common Share Repurchase Program
-
Nuclear Medicine/ Radiopharmaceutical/Logistic - Loos, France, RLG, Isovital Headquarter, Jan 8th 2024 : “Life Couriers acquires Isovital and the RLG group to create the global logistic leader for
-
Global Retailers Choose Dayforce to Optimize Workforce Planning and the Frontline Employee Experience
-
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
-
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
-
Alliance Trust PLC - Net Asset Value
-
Form 8.3 - Dechra Pharmaceuticals PLC
-
COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in
-
Bird Joint Venture Awarded The Alliance Development Agreement To Deliver The East Harbour Transit Hub In Toronto
-
NowVertical Announces Board and Management Changes Enhancing Capital Markets, Financial Governance and Operational Expertise
-
Transactions in connection with share buy-back program
-
Net Asset Value(s)
-
Novotech Executive Team at J.P. Morgan Healthcare Conference: Global CRO Designed for Biotechs Across 25 Regions
-
Ambrx Announces Sale to Johnson & Johnson
-
Ambrx Announces Sale to Johnson & Johnson
-
Gildan Activewear Board of Directors Issues Open Letter to Shareholders and Sets Record Straight on Browning West’s Misguided Campaign to Reinstall Former Gildan CEO
-
Shawcor Ltd. Legally Changes Corporate Name to Mattr Corp.
